Duloxetine and Neurofeedback Training for Chemotherapy-Induced Peripheral Neuropathy
Phase 2
380
about 6.5 years
18+
2 sites in TX
What this study is about
This trial is testing whether duloxetine and neurofeedback training are effective in treating chemotherapy-induced peripheral neuropathy. Duloxetine is a medication that increases certain brain chemicals to help relieve depression and peripheral neuropathy. Neurofeedback training uses an EEG to measure brain wave activity and may teach patients with peripheral neuropathy how to change their brain waves to lower feelings of neuropathy and improve quality of life.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Participate in Neurofeedback
- 2.Quality-of-Life Assessment
- 3.Questionnaire Administration
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
duloxetine (SNRI; increases serotonin and norepinephrine levels)
oral (Delayed Release Oral Capsule)
Primary: Change in Pain Quality Assessment Scale (PQAS) unpleasantness score
Secondary: Change in cancer-related symptoms, Change in quality of life, Evaluation of patients who will require more sessions of NFB to achieve relief of symptoms
monitoring
Oncology